PopeJEDeerTRBruelBMFalowskiS.Clinical uses of intrathecal therapy and its placement in the pain care algorithm. Pain Pract. 2016;16(8):1092-1106. doi:10.1111/papr.12438
2.
EldabeSDuarteRThomsonS, et al. Intrathecal drug delivery for the management of pain and spasticity in adults: British Pain Society’s recommendations for best clinical practice [published online ahead of print September 7, 2024]. Br J Pain. doi:10.1177/20494637241280356
3.
NauRBleiCEiffertH.Intrathecal antibacterial and antifungal therapies. Clin Microbiol Rev. 2020;33(3):e00190-19. doi:10.1128/CMR.00190-19
4.
DeerTRPopeJEHayekSM, et al. The Polyanalgesic Consensus Conference (PACC): recommendations on intrathecal drug infusion systems best practices and guidelines. Neuromodulation. 2017;20(2):96-132. doi:10.1111/ner.12538
5.
DeerTRHayekSMGriderJS, et al. The Polyanalgesic Consensus Conference (PACC)®: intrathecal drug delivery guidance on safety and therapy optimization when treating chronic noncancer pain. Neuromodulation. 2024;27(7):1107-1139. doi:10.1016/j.neurom.2024.03.003
Ortega GarcíaMPMínguez MartíALópez AlarcónMD, et al. Compounding of drug admixtures for intrathecal treatment of pain. Rev Soc Esp Dolor. 2012;19(4):217-224.
9.
SorrieulJRobertJBlanchetA, et al. Physicochemical stability study of the morphine-bupivacaine-ziconotide association. Neuromodulation. 2024;27(7):1149-1163. doi:10.1016/j.neurom.2023.11.009
10.
RobertJSorrieulJDupoironD, et al. Physicochemical stability study of the morphine-ropivacaine-ziconotide association in implantable pumps for intrathecal administration. Neuromodulation. 2023;26(6):1179-1194. doi:10.1016/j.neurom.2021.10.002
